Wee all do Enumerate but it's all about PYC actually delivering they've been in the game long enough it's about being to commercialise it.
Maybe Roche will get bitten in the bum twice who knows. When they left RNAi with frustration & in amongst their big restructure Arrowhead picked up their facilities, science & took on the staff. It only took a few years before they overcame what Roche had difficulties with in DPC & achieving the EET + they got a first drug in clinic. Maybe it will be the same story for PYC shoving it back in Roche;s face a few years after they walked from the deal without a license.
On the Novartis thing I think someone will pick Novartis RNAi discards in the not to distant future. Maybe Anylam again.
Anyway it's all about PYC finally being able to commercialise something & move out of the lab, still yet to see anything in humans in the 10+ years ?
Hopefully 2014 is the year & we do see Janssen move forward.
PYC Price at posting:
2.8¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)